Skip to main content

COVID-19 Boosters in Rheumatic Disease: Does Timing Matter more than Dose Count for Mortality?

Drs. Licia Mota and Vitor Cruz | Abstract 0901 | ACR 2026
 

Transcription

Hello, I'm Lisa Mota, rheumatologist from Brazil, reporting for RheumNow from ACR Convergences 2026 in Orlando. And I'm here with Dr. Victor Cruz that has just presented his study at ACR. And Victor, what could you tell us about your study?

First, I would like to thank Lisa and RheumNow for the opportunity to share our data. Here we conduct a retrospective nationwide cohort study in Brazil using data from the public health system surveillance database.

We included 918 patients with IMDs hospitalized for COVID-19 from 2022 to 2024, and we identified four independent determinants of in-hospital mortality: increase in age, black race, immunosuppression, and some comorbidities were also associated with higher odds of death — like heart disease and diabetes.

And our key finding was that the long time since the last booster was associated with higher odds of death. In fact, double the odds of death for each additional month from the booster.

So our key message was: we have to keep your patients up to date on COVID-19 vaccinations. So very important message, and stay tuned for more from RheumNow.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×